Actinium Pharmaceuticals, Inc. (ATNM) Total liabilities 2021–2025
Actinium Pharmaceuticals, Inc. (ATNM) total liabilities at each fiscal year-end, per SEC filings.
$43.9MFY2025 · since FY2021: $6.8M → $43.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $43.9M | — |
| FY2023 | $45.1M | -5.5% |
| FY2022 | $47.7M | +597.2% |
| FY2021 | $6.8M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ATNM financial trends
ATNM RevenueATNM Net incomeATNM Net marginATNM Gross profitATNM Gross marginATNM Operating incomeATNM Operating marginATNM Operating cash flowATNM Free cash flowATNM Capital expendituresATNM Return on equityATNM Stock buybacksATNM Dividends paidATNM Total assetsATNM Shareholders’ equityATNM overview →